Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
C656265-1ml
|
1ml |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$330.90
|
|
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Biochemical and Physiological Mechanisms | CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV) , with excellent cellular antiviral activity ( EC 90 =270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydro |
| Storage Temp | Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV) , with excellent cellular antiviral activity ( EC 90 =270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH) , which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools In Vitro CHIKV-IN-2 (compound 8q) is a potent pan-alphavirus inhibitor, with EC 90 s of 0.85-2.5 μM for CHIKV clinical isolates and attenuated vaccine strains. CHIKV-IN-2 is active against alphavirus VEEV (EC 90 =0.40 μM) as well as flaviviruses such as West Nile Virus (WNV, EC 90 =0.20 μM) and Dengue Virus Strain-2 (DENV-2, EC 90 =0.60 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CHIKV-IN-2 (compound 8q) (80 mg/kg; i.p. twice a day for 3 days) significantly decreases infectious CHIKV dissemination to other tissues of mice . CHIKV-IN-2 (40 mg/kg; p.o., i.p., s.c.) exhibits moderate bioavailability (F=41%, 43%, 4%), terminal elimination half-life (t 1/2 =9.9, 18.5, 18.6 h) and C max (642, 858, 90 ng/mL) in mice . CHIKV-IN-2 (1 mg/kg; i.v.) exhibits terminal elimination half-life (t 1/2 = 2.02 h) and AUC (497 h•ng/mL) in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female and male C57BL/6 mice Dosage: 80 mg/kg Administration: I.p. twice a day for 3 days Result: Failed to inhibit virus loads at the site of infection. Decreased virus dissemination to other tissues. Animal Model: Male C57BL/6 mice were challenged with CHIKV in the right footpad Dosage: 1 mg/kg for i.v. and 40 mg/kg for p.o., i.p., s.c. (Pharmacokinetic Analysis) Administration: I.v., p.o., i.p., s.c. Result: I.v.: t 1/2 = 2.02 h; AUC=497 h•ng/mL. P.o.: F=41%; t 1/2 =9.9 h; C max =642 ng/mL. I.p.: F=43%; t 1/2 =18.5 h; C max =858 ng/mL. S.c.: F=4%; t 1/2 =18.6 h; C max =90 ng/mL. IC50& Target:EC90: 270 nM (Chikungunya virus), Dihydroorotate Dehydrogenase |
| Smiles | CC(C)(C#N)C1=CC=C(C=C1)NC(=O)C2=C(C=C3CCCCCC3=C2)OC |
|---|---|
| Molecular Weight | 362.46 |